|1.||Wood, Jeanette: 11 articles (12/2014 - 07/2002)|
|2.||Laurent, Dirk: 10 articles (04/2014 - 11/2003)|
|3.||Prous, J R: 7 articles (06/2007 - 01/2003)|
|4.||Rabasseda, X: 7 articles (06/2007 - 01/2003)|
|5.||Wood, J: 7 articles (04/2005 - 03/2000)|
|6.||Laurent, D: 6 articles (09/2012 - 04/2005)|
|7.||Morgan, Bruno: 5 articles (04/2014 - 11/2003)|
|8.||Lebwohl, David: 5 articles (07/2011 - 06/2006)|
|9.||Drevs, Joachim: 5 articles (06/2010 - 07/2002)|
|10.||Schnell, Christian: 5 articles (03/2008 - 03/2004)|
11/01/2009 - "This method has been used to determine plasma vatalanib concentrations in patients with advanced solid tumor, enrolled in a phase I pharmacokinetic trial with the drug."
11/01/2006 - "Disposition and biotransformation of vatalanib were studied in an open-label, single-center study in patients with advanced cancer. "
05/15/2014 - "Notably, intermittent PTK787 treatment also facilitated long-term tumor regression. "
12/01/2013 - "DCE-MRI showed a significant increase in tumor size after vatalanib treatment. "
06/01/2010 - "Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo."
|2.||Colorectal Neoplasms (Colorectal Cancer)
05/20/2011 - "Vatalanib in advanced colorectal cancer: two studies with identical results."
07/01/2006 - "For other agents, such as vatalanib, contrasting outcomes in metastatic colorectal cancer patients have been reported: the final results of these trials are expected in 2006. "
04/01/2007 - "Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer."
11/01/2003 - "Current studies with PTK787, an oral inhibitor of vascular endothelial growth factor in colorectal cancer."
05/01/2005 - "Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial."
11/01/2010 - "We examined the combined effects of TM-MS and vatalanib in a rat orthotopic glioma model and found TM-MS offered a greater tumor inhibition than TM, and combination treatment with both of them improved the survival time versus single agent therapy. "
01/01/2010 - "This study was to determine the changes in tumor size, vascular permeability, fractional plasma volume and expression of VEGFR2 in PTK787 treated U-251 glioma rat model by in vivo magnetic resonance imaging (MRI) and single photon emission computed tomography (SPECT). "
11/01/2010 - "The results suggest that TM-MS can more effectively inhibit tumor than TM, and combination treatment with TM-MS and vatalanib inhibits tumor growth and angiogenesis and may prove to be a promising therapy for malignant gliomas."
11/01/2010 - "Vatalanib, as anti-angiogenic agent, has also shown anti-tumor activity with malignant gliomas. "
01/01/2010 - "Seven days after implantation of U251 glioma cells, animals were treated with either PTK787 or vehicle-only for two weeks, and then tumor size, tumor vascular permeability transfer constant (K(trans)), fractional plasma volume (fPV) and expression of VEGFR2 and other relevant angiogenic factors were assessed by in vivo MRI and SPECT (Tc-99-HYNIC-VEGF), and by immunohistochemistry and western blot analysis. "
|4.||Hepatocellular Carcinoma (Hepatoma)
05/01/2005 - "In addition, PTK787 induced growth arrest in hepatocellular carcinoma cells, which was associated with G1 arrest and partial G2-M block. "
05/01/2005 - "The in vitro effects of PTK787 on proliferation, apoptosis, and cell cycle distribution in human hepatocellular carcinoma cell lines were also studied. "
05/01/2005 - "In conclusion, this study showed that PTK787 is a potent inhibitor of tumor growth in hepatocellular carcinoma by both antiangiogenic effect and direct effects on tumor cell proliferation and apoptosis. "
05/01/2005 - "Oral administration of PTK787 resulted in a significant reduction in tumor volume and microvessel formation of hepatocellular carcinoma xenografts in nude mice. "
09/01/2006 - "High doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treatment of hepatocellular carcinoma: dual effects on cancer cell and angiogenesis."
|5.||Melanoma (Melanoma, Malignant)
10/01/2010 - "A phase 2 study of vatalanib in metastatic melanoma patients."
10/01/2010 - "Adults with pathologically confirmed metastatic melanoma, WHO Performance status 0-2, and adequate haematological, hepatic and renal function, were treated with vatalanib until disease progression. "
01/01/2008 - "It was 4-10 fold more potent than PTK787 in inhibiting the growth of T47D breast cancer cells, DU145 and PC-3 prostate cancer cells, LL/2 murine Lewis lung cancer cells and B16F0 melanoma cells."
05/01/2007 - "In this study, the effectiveness of PTK787/ZK 222584 and radiation on canine oral melanoma xenografts was assessed. "
02/01/2011 - "C57Bl6/J mice carrying B16/PDGF-BB mouse melanoma tumors were treated daily with vatalanib (25 mg/kg), imatinib (100 mg/kg), or a combination of these drugs. "
|2.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|3.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|4.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|5.||Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)
|10.||erlotinib (CP 358,774)
|2.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)